Just days after the other two drugmakers dropped their prices, Sanofi is capping the cost of its most prescribed insulin at $35 for the privately insured, as a price gouging lawsuit against all three drugmakers gets underway.

Americans have a pessimistic view of public health, even as most report their own health as mostly good.

Observers say that while capping the cost of insulin at $35 a month benefits consumers, it doesn't strengthen Lilly's legal arguments since the company and others raised list prices by 150% over five years, alleges one lawsuit.

"We're going to level the playing field and make this lifesaving drug more affordable for all who need it by putting an end to big pharma's big profit scheme," Attorney General Rob Bonta says.